UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549



FORM 8-K


CURRENT REPORT


Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934



Date of Report (Date of earliest event reported):       May 26, 2017




VITRO DIAGNOSTICS, INC.
(Exact Name of Registrant as Specified in its Charter)



       Nevada       

       0-17378       

    84-1012042    

(State or other jurisdiction
of incorporation)

Commission File
Number

(I.R.S. Employer Identification number)



4621 Technology Drive, Golden CO  80403
(Address of principal executive offices)                    (Zip Code)


Registrant's telephone number, including area code:    (303) 999-2130


______________________________________________________

(Former name or former address, if changed since last report)



___

Written communications pursuant to Rule 425 under the Securities Act

___

Soliciting material pursuant to Rule 14a-12 under the Exchange Act

___

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act

___

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act






ITEM 5.02

ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN

OFFICERS


On May 26, 2017, John R. Evans, age 62, was elected to serve as a member of the Board of Directors of the Company and appointed to the position of Chief Financial Officer.   Biographical information regarding Mr. Evans can be found in the Company’s Current Report on Form 8-K dated March 23, 2017, previously filed with the commission on March 29, 2017.


Mr. Evans will continue to receive his consulting fee of $10,000 per month, as previously reported


SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


 

 

Vitro Diagnostics, Inc.
(Registrant)

 

 

 

 

Dated:

May 26, 2017

/s/ James R. Musick

 

 

James R. Musick, President and Chief Executive Officer




2